South Korea · Delayed Price · Currency is KRW DuChemBIO Statistics
Total Valuation
DuChemBIO has a market cap or net worth of KRW 180.84 billion. The enterprise value is 186.36 billion.
| Market Cap | 180.84B |
| Enterprise Value | 186.36B |
Important Dates
The next estimated earnings date is Thursday, August 13, 2026.
| Earnings Date | Aug 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
DuChemBIO has 28.34 million shares outstanding. The number of shares has increased by 2.70% in one year.
| Current Share Class | 28.34M |
| Shares Outstanding | 28.34M |
| Shares Change (YoY) | +2.70% |
| Shares Change (QoQ) | -0.93% |
| Owned by Insiders (%) | 9.36% |
| Owned by Institutions (%) | 0.14% |
| Float | 11.01M |
Valuation Ratios
The trailing PE ratio is 25.79.
| PE Ratio | 25.79 |
| Forward PE | n/a |
| PS Ratio | 4.54 |
| PB Ratio | 3.61 |
| P/TBV Ratio | 5.57 |
| P/FCF Ratio | 16.90 |
| P/OCF Ratio | 15.67 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 11.66, with an EV/FCF ratio of 17.42.
| EV / Earnings | 26.72 |
| EV / Sales | 4.68 |
| EV / EBITDA | 11.66 |
| EV / EBIT | 22.74 |
| EV / FCF | 17.42 |
Financial Position
The company has a current ratio of 1.69, with a Debt / Equity ratio of 0.45.
| Current Ratio | 1.69 |
| Quick Ratio | 1.57 |
| Debt / Equity | 0.45 |
| Debt / EBITDA | 1.41 |
| Debt / FCF | 2.09 |
| Interest Coverage | 6.61 |
Financial Efficiency
Return on equity (ROE) is 14.91% and return on invested capital (ROIC) is 13.43%.
| Return on Equity (ROE) | 14.91% |
| Return on Assets (ROA) | 7.10% |
| Return on Invested Capital (ROIC) | 13.43% |
| Return on Capital Employed (ROCE) | 13.55% |
| Weighted Average Cost of Capital (WACC) | 4.47% |
| Revenue Per Employee | 316.01M |
| Profits Per Employee | 55.35M |
| Employee Count | 126 |
| Asset Turnover | 0.56 |
| Inventory Turnover | 17.57 |
Taxes
In the past 12 months, DuChemBIO has paid 348.90 million in taxes.
| Income Tax | 348.90M |
| Effective Tax Rate | 4.76% |
Stock Price Statistics
The stock price has decreased by -40.32% in the last 52 weeks. The beta is 0.02, so DuChemBIO's price volatility has been lower than the market average.
| Beta (5Y) | 0.02 |
| 52-Week Price Change | -40.32% |
| 50-Day Moving Average | 8,687.00 |
| 200-Day Moving Average | 9,452.95 |
| Relative Strength Index (RSI) | 19.55 |
| Average Volume (20 Days) | 42,680 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, DuChemBIO had revenue of KRW 39.82 billion and earned 6.97 billion in profits. Earnings per share was 247.40.
| Revenue | 39.82B |
| Gross Profit | 15.11B |
| Operating Income | 8.03B |
| Pretax Income | 7.32B |
| Net Income | 6.97B |
| EBITDA | 15.82B |
| EBIT | 8.03B |
| Earnings Per Share (EPS) | 247.40 |
Balance Sheet
The company has 16.82 billion in cash and 22.33 billion in debt, with a net cash position of -5.52 billion or -194.61 per share.
| Cash & Cash Equivalents | 16.82B |
| Total Debt | 22.33B |
| Net Cash | -5.52B |
| Net Cash Per Share | -194.61 |
| Equity (Book Value) | 50.11B |
| Book Value Per Share | 1,780.31 |
| Working Capital | 12.48B |
Cash Flow
In the last 12 months, operating cash flow was 11.54 billion and capital expenditures -838.88 million, giving a free cash flow of 10.70 billion.
| Operating Cash Flow | 11.54B |
| Capital Expenditures | -838.88M |
| Depreciation & Amortization | 7.79B |
| Net Borrowing | -5.24B |
| Free Cash Flow | 10.70B |
| FCF Per Share | 377.46 |
Margins
Gross margin is 37.95%, with operating and profit margins of 20.17% and 17.52%.
| Gross Margin | 37.95% |
| Operating Margin | 20.17% |
| Pretax Margin | 18.39% |
| Profit Margin | 17.52% |
| EBITDA Margin | 39.72% |
| EBIT Margin | 20.17% |
| FCF Margin | 26.87% |
Dividends & Yields
DuChemBIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.70% |
| Shareholder Yield | -2.70% |
| Earnings Yield | 3.86% |
| FCF Yield | 5.92% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
DuChemBIO has an Altman Z-Score of 7.71 and a Piotroski F-Score of 6.
| Altman Z-Score | 7.71 |
| Piotroski F-Score | 6 |